The analysis for CA125 levels in the blood is a helpful method for examining the chances of ovarian cancer and can aid in detecting other kinds of cancer amongst patients in primary care, as per research submitted at the 2019 NCRI Cancer Conference. Though the CA125 test is at present in use in several nations worldwide, this is the first large investigate to look at how well it executes in general practice for examining women having possible signs and symptoms of ovarian cancer. The scientists reported their results can guide women and their general practitioners on whether more persistent tests are required to analyze for ovarian and other cancers.
They also stated that clinical guidelines can now be advanced to make sure urgent referrals are done for women most at major risk. The research was conducted by Dr. Garth Funston—Clinical Research Fellow at the CU (University of Cambridge). He added, “Less than half of the women having ovarian cancer survive for about 5 Years after the identification. Most of the women are not identified until the disease is developed, which makes it more complicated to cure.” During the study, they discovered that 10% of women having abnormally high levels of CA125 in their blood were detected to have ovarian cancer. This figure is higher than earlier thought and 10 folds greater than the projections given in the UK’s 2011 National Institute for Health and Care Excellence guiding principles on ovarian cancer diagnosis.
On a related note, a study reported that the use of IUD (intrauterine device) might decrease the occurrence of ovarian cancer. IUD use amongst reproductive women is linked with a lowered prevalence of ovarian cancer, as per to research published in Obstetrics & Gynecology. Lindsay J. Wheeler—from the UC Aurora (University of Colorado in Aurora)—along with colleagues led a systematic literature review to analyze the association amid IUD use and perils for ovarian cancer. They found that ever use of an IUD was linked with a reduced risk for incident ovarian cancer.